Is the IXJ ETF a good investment? Here’s where you start…
The iShares IXJ ETF provides investors with a targeted exposure to over 100 global healthcare companies. This includes companies in the pharmaceutical, biotechnology, and medical device space.
According to our most recent data, the IXJ ETF had $1151.62 million of money invested. With IXJ’s total funds under management (FUM) figure over $100 million, the ETF meets our team’s minimum investment criteria for FUM levels. As a general rule, our team draws the line at $100 million for ETFs in the International shares sector because we believe that, relative to smaller ETFs, achieving this amount of FUM lowers the chance that the ETF issuer will close the ETF.
Get our team’s IXJ ETF review, available free when you click this link: access the free investment report.
A quick take of the RDV ETF
The Russell Investments RDV ETF invests in a diversified portfolio of high-yielding âblue chipâ Australian companies. This ETF tracks this Russell Australia High Dividend Index.
With our numbers for July 2022, RDV’s FUM stood at $237.76 million. Since the RDV’s FUM is over $100 million, our investing team would say the ETF has met our minimum criteria for the total amount invested, otherwise known as FUM. A very sustainable ETF in the Index sector should be able to scale well and become profitable for the ETF issuer.
A look at the RDV ETF fee load?
Russell Investments, the ETF issuer, charges a yearly management fee of 0.34% for the RDV ETF. Meaning, if you invest $2,000 for a full year from now you can expect to pay a management fee of around $6.80.
This management fee is below the average for all ETFs on our Best ETFs Australia list of ETFs. However, you might still be able to find a cheaper ETF for less.
Did you know: you can get our full ETF review of RDV by clicking here?
